Notice2023-06687
Bulk Manufacturer of Controlled Substances Application: Purisys, LLC
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 31, 2023
Issuing agencies
Justice DepartmentDrug Enforcement Administration
Abstract
Purisys, LLC, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 62 (Friday, March 31, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 62 (Friday, March 31, 2023)]
[Notices]
[Pages 19325-19327]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-06687]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1172]
Bulk Manufacturer of Controlled Substances Application: Purisys,
LLC
AGENCY: Drug Enforcement Administration, Justice.
[[Page 19326]]
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Purisys, LLC, has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
May 30, 2023. Such persons may also file a written request for a
hearing on the application on or before May 30, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on February 16, 2023, Purisys, LLC, 1550 Olympic Drive,
Athens, Georgia 30601-1602, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Cathinone................................ 1235 I
Gamma Hydroxybutyric Acid................ 2010 I
Ibogaine................................. 7260 I
Lysergic acid diethylamide............... 7315 I
Marihuana Extract........................ 7350 I
Marihuana................................ 7360 I
Tetrahydrocannabinols.................... 7370 I
2,5-Dimethoxyamphetamine................. 7396 I
3,4-Methylenedioxyamphetamine............ 7400 I
3,4-Methylenedioxy-N-ethylamphetamine.... 7404 I
3,4-Methylenedioxymethamphetamine........ 7405 I
5-Methoxy-N,N-dimethyltryptamine......... 7431 I
Diethyltryptamine........................ 7434 I
Dimethyltryptamine....................... 7435 I
Psilocybin............................... 7437 I
Psilocyn................................. 7438 I
5-Methyoxy-N,N-diisopropyltryptamine..... 7439 I
Codeine-N-oxide.......................... 9053 I
Dihydromorphine.......................... 9145 I
Heroin................................... 9200 I
Hydromorphinol........................... 9301 I
Morphine-N-oxide......................... 9307 I
Normorphine.............................. 9313 I
Norlevorphanol........................... 9634 I
Amphetamine.............................. 1100 II
Lisdexamfetamine......................... 1205 II
Methylphenidate.......................... 1724 II
Pentobarbital............................ 2270 II
Nabilone................................. 7379 II
Cocaine.................................. 9041 II
Codeine.................................. 9050 II
Dihydrocodeine........................... 9120 II
Oxycodone................................ 9143 II
Hydromorphone............................ 9150 II
Ecgonine................................. 9180 II
Hydrocodone.............................. 9193 II
Levorphanol.............................. 9220 II
Meperidine............................... 9230 II
Meperidine intermediate-A................ 9232 II
Meperidine intermediate-B................ 9233 II
Meperidine intermediate-C................ 9234 II
Methadone intermediate................... 9250 II
Methadone intermediate................... 9254 II
Morphine................................. 9300 II
Oripavine................................ 9330 II
Thebaine................................. 9333 II
Opium tincture........................... 9630 II
Opium, powdered.......................... 9639 II
Opium, granulated........................ 9640 II
Oxymorphone.............................. 9652 II
Noroxymorphone........................... 9668 II
Alfentanil............................... 9737 II
Sufentanil............................... 9740 II
Carfentanil.............................. 9743 II
Tapentadol............................... 9780 II
Fentanyl................................. 9801 II
------------------------------------------------------------------------
[[Page 19327]]
The company plans to bulk manufacture the listed controlled
substances for the production of active pharmaceutical ingredients
(API) and analytical reference standards for sale to its customers. The
company plans to manufacture the above listed controlled substances as
clinical trial and starting materials to make compounds for
distribution to its customers. No other activities for these drug codes
are authorized for this registration.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023-06687 Filed 3-30-23; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on March 31, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.